SEARCH

SEARCH BY CITATION

References

  • 1
    Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 9971008
  • 2
    Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003; 30: 765776
  • 3
    Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66 (6 Suppl. 1): 3563
  • 4
    Brimo F, Vollmer RT, Case B, Aprikian A, Kassouf W, Auger M. Accuracy of urine cytology and the significance of an atypical category. Am J Clin Pathol 2009; 132: 785793
  • 5
    Yafi FA, Brimo F, Auger M, Aprikian A, Tanguay S, Kassouf W. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol Oncol 2013; doi: 10.1016/j.urolonc.2012.09.011. [Epub ahead of print]
  • 6
    Karakiewicz PI, Benayoun S, Zippe C et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006; 97: 9971001
  • 7
    Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 23142330
  • 8
    Nabi G, Greene D, O'Donnell MO. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? J Clin Pathol 2004; 57: 365368
  • 9
    Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 2008; 15: 279286
  • 10
    Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008; 26: 646651
  • 11
    Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168: 19501954
  • 12
    Skacel M, Fahmy M, Brainard JA et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in most patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169: 21012105
  • 13
    Yoder BJ, Skacel M, Hedgepeth R et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007; 127: 295301
  • 14
    Caraway NP, Khanna A, Fernandez RL et al. Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol 2010; 118: 259268
  • 15
    Galvan AB, Salido M, Espinet B et al. A multicolor fluorescence in situ hybridization assay: a monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: a prospective study. Cancer Cytopathol 2011; 119: 395403
  • 16
    Ferra S, Denley R, Herr H, Dalbagni G, Jhanwar S, Lin O. Reflex UroVysion testing in suspicious urine cytology cases. Cancer 2009; 117: 714
  • 17
    Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008; 179: 21642169
  • 18
    Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2010; 183: 6267
  • 19
    Bollmann M, Heller H, Bankfalvi A, Griefingholt H, Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005; 95: 12191225
  • 20
    Edge SB, American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2010: xiv, 648 pp
  • 21
    Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2005; 13: 143153
  • 22
    Raitanen MP, Aine RA, Kaasinen ES et al. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive? Scand J Urol Nephrol 2002; 36: 213217
  • 23
    Lotan Y, Shariat SF, Schmitz-Drager BJ et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 2010; 28: 441448
  • 24
    Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 2011; 108: 11191123
  • 25
    Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000; 53: 676680
  • 26
    Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001; 21 (1B): 765769
  • 27
    Mengual L, Marin-Aguilera M, Ribal MJ et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol 2007; 52: 752759
  • 28
    Savic S, Zlobec I, Thalmann GN et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 2009; 124: 28992904
  • 29
    Kamat AM, Dickstein RJ, Messetti F et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial. J Urol 2012; 187: 862867
  • 30
    Raab SS, Grzybicki DM, Vrbin CM, Geisinger KR. Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol 2007; 127: 946953